• NewGenIvf Group posted fiscal year 2025 net profit attributable to shareholders of USD 9.9 million, driven primarily by a bargain purchase gain tied to Nodexus and Microsort acquisitions.
• Total assets climbed to USD 32.7 million as of Dec. 31, 2025, from USD 3.6 million a year earlier.
• Completed acquisition of advanced cytometry intellectual property in July 2025, later valued at USD 17.9 million by a big-four accounting firm, generating total bargain purchase gain of USD 19.2 million.
• Authorized USD 2 million share repurchase program in November 2025; continued diversification push spanning digital asset innovation through NewGenDigital and health supplements through NewGenSup.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewGenIvf Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605040830PRIMZONEFULLFEED9712241) on May 04, 2026, and is solely responsible for the information contained therein.